Gujarat Themis Biosyn Limited Announces Financial Results, Recommends Dividend, and Approves Preferential Issue
Gujarat Themis Biosyn Limited (GTBL) reported on its Board meeting, confirming the approval of its audited financial results for the quarter and year ended March 31, 2026. During the meeting, the Board also recommended a final dividend and approved key strategic moves, including the appointment of a Cost Auditor and the proposal for a preferential issue of equity shares.Dividend and Auditing Decisions
The Board of Directors recommended a final dividend of Re. 0.67 per equity share, based on a face value of Re. 1/each. This recommendation aggregates to Rs. 7,30,06,728/- for the Financial Year ended March 31, 2026. The payment of this dividend remains subject to the approval of the shareholders at the ensuing Annual General Meeting.Furthermore, the Board approved the appointment of M/s. Raja Dutta & Co., Cost Accountants (FRN - 101555), as the Cost Auditor of the Company for the Financial Year 2026-27.
Proposed Preferential Issue
The Board also considered and approved a proposal for the preferential issue of equity shares to Non-Promoters. The issuance can proceed through preferential allotment or other combinations permitted by law. To manage this process, the Board constituted a Preferential Issue Committee consisting of:- Dr. Dinesh Patel (Non-Executive Director)
- Mr. Rajneesh Anand (Non-Executive Director)
- Mr. Hitesh Gajaria (Independent Director)
- Mr. Nihar Parikh (Independent Director)
- Ms. Kirandeep Madan (Independent Director)
Financial Performance Highlights
The company released comprehensive audited financial results for the quarter and the year ended March 31, 2026, alongside balance sheet and cash flow statements. The financial results indicate the following annual performance figures (amounts are in INR Lakhs):| Particulars | Year Ended March 31, 2026 (Audited) | Year Ended March 31, 2025 (Audited) |
|---|---|---|
| Total Income | 16,825.09 | 15,323.23 |
| Total Expenses | 10,616.08 | 8,769.44 |
| Net Profit after tax | 4,668.15 | 4,877.17 |
| Total Comprehensive Income | 4,668.65 | 4,882.26 |
| Earnings Per Share (Basic and Diluted) | 4.28 | 4.48 |
The Balance Sheet figures as of March 31, 2026, compared to March 31, 2025, are presented below:
| Particulars | As at March 31, 2026 | As at March 31, 2025 |
|---|---|---|
| ASSETS (TOTAL) | 150,342.66 | 30,131.25 |
| Non-Current Assets | 41,464.28 | 24,933.94 |
| Total Current Assets | 8,878.38 | 5,197.32 |
| EQUITY AND LIABILITIES (TOTAL) | 50,342.66 | 30,131.25 |
| Equity (Total) | 28,776.78 | 24,838.20 |
| Non-Current Liabilities | 13,651.05 | 3,237.09 |
| Current Liabilities | 7,914.83 | 2,055.97 |
The Cash Flow Statement reveals the following key trends for the period ended March 31, 2026:
| Cash Flow Activity | Year ended March 31, 2026 (Audited) | Year ended March 31, 2025 (Audited) |
|---|---|---|
| Net cash inflow from operating activities | 4,877.73 | 9,106.19 |
| Net cash outflow from investing activities | (17,227.65) | (11,181.82) |
| Net cash inflow from financing activities | 11,492.68 | 2,601.43 |
| Net increase in cash and cash equivalents | (857.24) | 525.80 |
For the full details of the financials, the full statement of results, balance sheet, and cash flow statement are available.
GUJTHEM Stock Price Movement
Shares of Gujarat Themis Biosyn Limited are rallying as of 3:22 PM in live trading, gaining 4.42% to reach ₹385. The momentum is backed by robust investor interest, as the stock sees over 584,211 shares traded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: